Zai Lab Limited

Ladies and gentlemen, thank you for standing by and welcome to Xilab full year and fourth quarter 2022 financial results conference call. Through the call, I'd like to remind you that the audience who are joining via the webcast can refer to the presentation slides and follow along with management presentation. The slides will be available for download in the Investor Relations section of ZayLab's website after this call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Any section will follow at that time. As a reminder, today's call is being recorded. It's now my pleasure to turn the floor over to Billy Chu, CF Financial Officer of ZayLab, who will make introductory comments.

Thank you, operator.

Good morning, good evening, and welcome, everyone. Xialab recently issued a press release providing the details of the company's full year 2022 financial results, as well as some recent product highlights and corporate updates. The press release is available in the investor relations section of the company's website at ir.xialaboratory.com. Today's call will be led by Dr. Samantha Du. Zylabs founder, chief executive officer, and chairperson. After Dr. Du provides opening remarks with an overview of 2022 highlights, Josh Smiley, chief operating officer, will further discuss key business updates and 2023 strategic priorities. Dr. Rafael Amado, president and head of global development oncology, We'll discuss advances with our oncology product candidates. Dr. Harold Reinhart, President and Head of Global Development, Neuroscience, Autoimmune, and Infectious Diseases, will speak about progress we have made in those three therapeutic areas. And I will discuss the performance of our marketed products and conclude with comments on our full year and fourth quarter financial results. Additional vectors will be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, Xilab will be making certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to our business plans and objectives, clinical trials, sales and revenue forecasts for our products and product candidates, regulatory applications, and commercial launches. Such forward-looking statements are not guarantees of future performance, and therefore, we should not put undue reliance upon them. These statements are subject to numerous risks and uncertainties, and actual results could differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. At this time, it is my pleasure to turn the call over to Xilab's founder, chief executive officer, and chairperson, Dr. Samantha Du.